Barry Fishman

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada.

Juno Pharmaceuticals Corp. specializes in bringing complex and high-value generic and biosimilar products to the Canadian market. The company is based in Mississauga, Canada, and has subsidiaries in Canada. The Juno management team possesses decades of pharmaceutical industry experience and has a track record of driving strategic growth through the identification of niche products and disciplined construction of robust product pipelines. Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry. The Canadian company was founded in 2019, and Mark Mantel has been the CEO of the company since 2022.